Morphine Modulates NFκB Activation in Macrophages

doi:10.1006/bbrc.1998.8415

Biochemical and Biophysical Research Communications

Volume 245, Issue 2, 17 April 1998, Pages 392-396

https://doi.org/10.1006/bbrc.1998.8415 Get rights and content

Abstract

Chronic use of morphine affects the immune system and predisposes an individual to opportunistic infections. Macrophages play an important role in conferring a first line of defense against invading pathogens. Understanding the mechanisms by which morphine affects the functioning of macrophages would have significant therapeutic benefit in treatment against infections such as HIV and AIDS related syndromes. Two of the major cytokines secreted by activated macrophages are Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α). Our studies show that morphine differentially modulates lipopolysaccharide (LPS) induced expression of IL-6 and TNF-α. Nanomolar concentrations of morphine synergize with LPS and augment the secretion of both IL-6 and TNF-α. However, at micromolar concentrations morphine inhibits LPS induced synthesis of IL-6 and TNF-α. Expression of both these cytokine genes is dependent on the activation of a transcription factor, NFκB. Interestingly, morphine treatment also modulated the activation of NFκB by LPS. Pretreatment with a low dose of morphine (nanomolar) resulted in an increase in NFκB activation. In contrast pretreatment with a high dose of morphine (micromolar) led to a significant decrease in NFκB activation. Furthermore unlike the augmentation which was naloxone reversible, the inhibition of NFκB by morphine was not reversed by naloxone, suggesting the involvement of a nonclassical opioid receptor.

References (27)

R. Pacifici et al.
Macrophage Functions in Drugs of Abuse treated mice
Int. J. Immunopharmac.
(1993)
E. Tubaro et al.
Methadone vs morphine: comparison of their effect on phagocytic functions
International Journal of Immunopharmacology
(1987)
E.Z. Tomei et al.
Effect of morphine on Fc-mediated phagocytosis by murine macrophages in vitro
J. Neuroimmunol.
(1997)
R. Pacifici et al.
Morphine affects cytostatic activity of macrophages by the modulation of nitric oxide release
Int. J. Immunopharmacol.
(1995)
R.V. House et al.
In vitro evaluation of fentanyl and meperidine for immunomodulatory
Immunology Letters
(1995)
C. Alicea et al.
Inhibition of primary murine macrophage cytokine production in vitro following treatment with the k-opioid against U50,488H
J. Neuroimmunol.
(1996)
J.J. Jessop et al.
Effect of high doses of morphine on Con-A induced lymphokine production in vitro
Immunopharmacol.
(1991)
D.G. Le Vier et al.
Immunotoxicological Profile of Morphine Sulfate in B6C3F1 female mice
Fund. Appld. Toxicol.
(1994)
S. Swingler et al.
Tumour necrosis factor alpha and interleukin-1 beta induce specific subunits of NFKB to bind the HIV-1 enhancer: characterisation of transcription factors controlling human immunodeficiency virus type 1 gene expression in neural cells
Biochem. Biophysic. Res. Comm.
(1994)
P.A. Baeuerle et al.
Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NFκB transcription factor
Cell
(1988)

S. Roy et al.

Effects of Opioids on the Immune System

Neurochemical Research

(1996)

K. Fecho et al.

Macrophage-derived nitric oxide is involved in the depressed con A-responsiveness of splenic lymphocytes from rats administered morphinein vivo.

J. Immunol.

(1994)

B.M. Sharp et al.

Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages

Endocrinology

(1985)

Cited by (146)

One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology
2023, Neuropharmacology
The transition from acute to chronic pain is an ongoing major problem for individuals, society and healthcare systems around the world. It is clear chronic pain is a complex multidimensional biological challenge plagued with difficulties in pain management, specifically opioid use. In recent years the role of the immune system in chronic pain and opioid pharmacology has come to the forefront. As a highly dynamic and versatile network of cells, tissues and organs, the immune system is perfectly positioned at the microscale level to alter nociception and drive structural adaptations that underpin chronic pain and opioid use. In this review, we highlight the need to understand the dynamic and adaptable characteristics of the immune system and their role in the transition, maintenance and resolution of chronic pain. The complex multidimensional interplay of the immune system with multiple physiological systems may provide new transformative insight for novel targets for clinical management and treatment of chronic pain.
This article is part of the Special Issue on “Opioid-induced changes in addiction and pain circuits”.
Immunosuppression by opioids: Mechanisms of action on innate and adaptive immunity
2023, Biochemical Pharmacology
Opioids are excellent analgesics for the clinical treatment of various types of acute and chronic pain, particularly cancer-related pain. Nevertheless, it is well known that opioids have some nasty side effects, including immunosuppression, which is commonly overlooked. As a result, the incidence of opportunistic bacterial and viral infections increases in patients with long-term opioid use. Nowadays, there are no effective medications to alleviate opioid-induced immunosuppression. Understanding the underlying molecular mechanism of opioids in immunosuppression can enable researchers to devise effective therapeutic interventions. This review comprehensively summarized the exogenous opioids-induced immunosuppressive effects and their underlying mechanisms, the regulatory roles of endogenous opioids on the immune system, the potential link between opioid immunosuppressive effect and the function of the central nervous system (CNS), and the future perspectives in this field.
Toll-like receptors change morphine-induced antinociception, tolerance and dependence: Studies using male and female TLR and signalling gene KO mice
2022, Brain, Behavior, and Immunity
Toll-like receptors (TLR) have been proposed as a site of action that alters opioid pharmacodynamics. However, a comprehensive assessment of acute opioid antinociception, tolerance and withdrawal behaviours in genetic null mutant strains with altered innate immune signalling has not been performed. Nor has the impact of genetic deletion of TLR2/4 on high-affinity opioid receptor binding. Here we show that diminished TLR signalling potentiates acute morphine antinociception equally in male and female mice. However, only male TIR8 null mutant mice showed reduced morphine analgesia. Analgesic tolerance was prevented in TLR2 and TLR4 null mutants, but not MyD88 animals. Withdrawal behaviours were only protected in TLR2^−/− mice. In silico docking simulations revealed opioid ligands bound preferentially to the LPS binding pocket of MD-2 rather than TLR4. There was no binding of [³H](-)-naloxone or [³H]diprenorphine to TLR4 in the concentrations explored. These data confirm that opioids have high efficacy activity at innate immune pattern recognition binding sites but do not bind to TLR4 and identify critical pathway and sex-specific effects of the complex innate immune signalling contributions to opioid pharmacodynamics. These data further support the behavioural importance of the TLR-opioid interaction but fail to demonstrate direct evidence for high-affinity binding of the TLR4 signalling complex to ligands.
Inhibitory effects of dynorphin 3-14 on the lipopolysaccharide-induced toll-like receptor 4 signalling pathway
2017, Peptides
Citation Excerpt :
For instance, morphine at micromolar concentrations was found to inhibit the LPS-induced interleukin-6 (IL-6) and TNF-α release associated with attenuation of NF-κB activation in mouse peritoneal macrophages. This effect however was not reversed by naloxone, indicating the involvement of a non-opioid receptor mechanism [15]. Furthermore, inhibition of LPS-induced NF-κB activation and subsequent IL-1β release following naloxone treatment in RAW264 cells was mediated by L-type calcium channels [16].
Dynorphin 1-17 (DYN 1-17) is biotransformed rapidly to a range of fragments in rodent inflamed tissue with dynorphin 3-14 (DYN 3-14) being the most stable and prevalent. DYN 1-17 has been shown previously to be involved in the regulation of inflammatory response following tissue injury, in which the biotransformation fragments of DYN 1-17 may possess similar features. This study investigated the effects of DYN 3-14 on lipopolysaccharide (LPS)-induced nuclear factor-kappaB/p65 (NF-κB/p65) nuclear translocation and the release of pro-inflammatory cytokines interleukin-1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in differentiated THP-1 cells. Treatment with DYN 3-14 (10 nM) resulted in 35% inhibition of the LPS-induced nuclear translocation of NF-κB/p65. Furthermore, DYN 3-14 modulated both IL-1β and TNF-α release; inhibiting IL-1β and paradoxically augmenting TNF-α release in a concentration-independent manner. A number of opioids have been implicated in the modulation of the toll-like receptor 4 (TLR4), highlighting the complexity of their immunomodulatory effects. To determine whether DYN 3-14 modulates TLR4, HEK-Blue™⁻hTLR4 cells were stimulated with LPS in the presence of DYN 3-14. DYN 3-14 (10 μM) inhibited TLR4 activation in a concentration-dependent fashion by suppressing the LPS signals around 300-fold lower than LPS-RS, a potent TLR4 antagonist. These findings indicate that DYN 3-14 is a potential TLR4 antagonist that alters cellular signaling in response to LPS and cytokine release, implicating a role for biotransformed endogenous opioid peptides in immunomodulation.
Dose-dependent effects of morphine on lipopolysaccharide (LPS)-induced inflammation, and involvement of multixenobiotic resistance (MXR) transporters in LPS efflux in teleost fish
2017, Environmental Pollution
Opioid drugs, such as morphine (MO), detected in aquatic environments worldwide, may harm fish due to their semi-persistence and ability to potently interact with molecular targets conserved across vertebrates. Here, we established a waterborne bacterial lipopolysaccharide (LPS) challenge assay with zebrafish embryos as a model to investigate chemically-induced disruption of the innate immune system, and used it to study the effects of MO exposure. Exposure to 1 mg/L MO resulted in pronounced immunosuppression, reflected in downregulation of several inflammation-related genes, including myd88, trif, traf6, p38, nfκb2, il-1β, il-8 and ccl34a. Fish exposed to 1 mg/L MO accumulated 11.7 ng/g (wet weight) of MO, a concentration comparable to that reported in blood of chronic drug abusers subject to higher infection rates. Surprisingly, exposure to lower MO concentrations (100 ng/L–100 μg/L) led to exacerbation of LPS-induced inflammation. Two ATP-binding cassette (ABC) transporters known to be involved in the xenobiotic efflux - abcb4 and abcc2, also known as multixenobiotic resistance (MXR) transporters - were downregulated at 100 ng/L MO. We hypothesized that ABC/MXR transporters could modulate the severity of inflammation by being involved in efflux of LPS, thus regulating its accumulation in the organism. Indeed, we could demonstrate that blocking of ABC/MXR transporters by an inhibitor, cyclosporine A, results in stronger inflammation, coinciding with higher LPS accumulation, as visualized with fluorescently labeled LPS. Our work demonstrates that MO can disrupt fish innate immune responses at environmentally relevant concentrations. We also provide evidence for a role of ABC/MXR transporters in LPS efflux in fish. These finding may be applicable across other taxa, as ABC transporters are evolutionary conserved. Since diverse environmentally present chemicals are known to interfere with ABC/MXR transporters' expression or activity, our discovery raises concerns about potential adverse effects of such compounds on the immune system responses in aquatic organisms.
The toll of opioid dependence: A research report on the possible role of Toll-like receptor-4 and related immune markers in opioid dependence
2023, Indian Journal of Psychiatry

View all citing articles on Scopus

¹: Corresponding author. Department of Surgery, Veterans Administration Medical Center, 1 Veterans Drive, Minneapolis, MN 55417. Fax: (612) 725-2227. E-mail:[email protected].

View full text

Regular ArticleMorphine Modulates NFκB Activation in Macrophages

Abstract

Int. J. Immunopharmac.

International Journal of Immunopharmacology

J. Neuroimmunol.

Int. J. Immunopharmacol.

Immunology Letters

J. Neuroimmunol.

Immunopharmacol.

Fund. Appld. Toxicol.

Biochem. Biophysic. Res. Comm.

Cell